249 related articles for article (PubMed ID: 20571429)
1. Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.
Priviero FB; Webb RC
J Cardiovasc Pharmacol; 2010 Sep; 56(3):229-33. PubMed ID: 20571429
[TBL] [Abstract][Full Text] [Related]
2. Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes.
Goulopoulou S; Hannan JL; Matsumoto T; Ogbi S; Ergul A; Webb RC
Am J Physiol Heart Circ Physiol; 2015 Jul; 309(2):H297-304. PubMed ID: 25957216
[TBL] [Abstract][Full Text] [Related]
3. The chemistry and biology of soluble guanylate cyclase stimulators and activators.
Follmann M; Griebenow N; Hahn MG; Hartung I; Mais FJ; Mittendorf J; Schäfer M; Schirok H; Stasch JP; Stoll F; Straub A
Angew Chem Int Ed Engl; 2013 Sep; 52(36):9442-62. PubMed ID: 23963798
[TBL] [Abstract][Full Text] [Related]
4. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
5. The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies.
Sharina IG; Sobolevsky M; Papakyriakou A; Rukoyatkina N; Spyroulias GA; Gambaryan S; Martin E
Br J Pharmacol; 2015 May; 172(9):2316-29. PubMed ID: 25536881
[TBL] [Abstract][Full Text] [Related]
6. NO-independent, haem-dependent soluble guanylate cyclase stimulators.
Stasch JP; Hobbs AJ
Handb Exp Pharmacol; 2009; (191):277-308. PubMed ID: 19089334
[TBL] [Abstract][Full Text] [Related]
7. Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation.
Hoffmann LS; Schmidt PM; Keim Y; Schaefer S; Schmidt HH; Stasch JP
Br J Pharmacol; 2009 Jul; 157(5):781-95. PubMed ID: 19466990
[TBL] [Abstract][Full Text] [Related]
8. NO- and haem-independent soluble guanylate cyclase activators.
Schmidt HH; Schmidt PM; Stasch JP
Handb Exp Pharmacol; 2009; (191):309-39. PubMed ID: 19089335
[TBL] [Abstract][Full Text] [Related]
9. Preconditioning with soluble guanylate cyclase activation prevents postischemic inflammation and reduces nitrate tolerance in heme oxygenase-1 knockout mice.
Wang WZ; Jones AW; Wang M; Durante W; Korthuis RJ
Am J Physiol Heart Circ Physiol; 2013 Aug; 305(4):H521-32. PubMed ID: 23771693
[TBL] [Abstract][Full Text] [Related]
10. Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation.
Meurer S; Pioch S; Pabst T; Opitz N; Schmidt PM; Beckhaus T; Wagner K; Matt S; Gegenbauer K; Geschka S; Karas M; Stasch JP; Schmidt HH; Müller-Esterl W
Circ Res; 2009 Jul; 105(1):33-41. PubMed ID: 19478201
[TBL] [Abstract][Full Text] [Related]
11. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
Fraccarollo D; Galuppo P; Motschenbacher S; Ruetten H; Schäfer A; Bauersachs J
Basic Res Cardiol; 2014 Jul; 109(4):421. PubMed ID: 24907870
[TBL] [Abstract][Full Text] [Related]
12. Exploring the potential of NO-independent stimulators and activators of soluble guanylate cyclase for the medical treatment of erectile dysfunction.
Gur S; Kadowitz PJ; Hellstrom WJ
Curr Pharm Des; 2010 May; 16(14):1619-33. PubMed ID: 20201788
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide and heat shock protein 90 activate soluble guanylate cyclase by driving rapid change in its subunit interactions and heme content.
Ghosh A; Stasch JP; Papapetropoulos A; Stuehr DJ
J Biol Chem; 2014 May; 289(22):15259-71. PubMed ID: 24733395
[TBL] [Abstract][Full Text] [Related]
14. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle.
Stasch JP; Schmidt P; Alonso-Alija C; Apeler H; Dembowsky K; Haerter M; Heil M; Minuth T; Perzborn E; Pleiss U; Schramm M; Schroeder W; Schröder H; Stahl E; Steinke W; Wunder F
Br J Pharmacol; 2002 Jul; 136(5):773-83. PubMed ID: 12086987
[TBL] [Abstract][Full Text] [Related]
15. Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress.
Zhou Z; Pyriochou A; Kotanidou A; Dalkas G; van Eickels M; Spyroulias G; Roussos C; Papapetropoulos A
Am J Physiol Heart Circ Physiol; 2008 Oct; 295(4):H1763-71. PubMed ID: 18757489
[TBL] [Abstract][Full Text] [Related]
16. Erectile Dysfunction in Heme-Deficient Nitric Oxide-Unresponsive Soluble Guanylate Cyclase Knock-In Mice.
Decaluwé K; Pauwels B; Boydens C; Thoonen R; Buys ES; Brouckaert P; Van de Voorde J
J Sex Med; 2017 Feb; 14(2):196-204. PubMed ID: 28161078
[TBL] [Abstract][Full Text] [Related]
17. New insights into the role of soluble guanylate cyclase in blood pressure regulation.
Buys E; Sips P
Curr Opin Nephrol Hypertens; 2014 Mar; 23(2):135-42. PubMed ID: 24419369
[TBL] [Abstract][Full Text] [Related]
18. Insight into the rescue of oxidized soluble guanylate cyclase by the activator cinaciguat.
Surmeli NB; Marletta MA
Chembiochem; 2012 May; 13(7):977-81. PubMed ID: 22474005
[TBL] [Abstract][Full Text] [Related]
19. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.
Evgenov OV; Pacher P; Schmidt PM; Haskó G; Schmidt HH; Stasch JP
Nat Rev Drug Discov; 2006 Sep; 5(9):755-68. PubMed ID: 16955067
[TBL] [Abstract][Full Text] [Related]
20. Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase.
Martin F; Baskaran P; Ma X; Dunten PW; Schaefer M; Stasch JP; Beuve A; van den Akker F
J Biol Chem; 2010 Jul; 285(29):22651-7. PubMed ID: 20463019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
